| Autor: |
Langworthy, Michael J., Hummer, Charles D., Ngai, Wilson, Hao, Lichen, Webner, David |
| Zdroj: |
Cartilage; December 2021, Vol. 13 Issue: Supplement 1 p1586S-1597S, 12p |
| Abstrakt: |
Objective Assess how treatment with the viscosupplement hylan G-F 20 relates to opioid prescriptions and intraarticular corticosteroid injections (IACS) in patients with osteoarthritis of the knee (OAK).Design Case-crossover; adult patients with OAK identified in a claims database were treated with hylan G-F 20 from July 1, 2007, to June 29, 2017. Opioid or IACS prescriptions in the 6 months before treatment were compared to the 6 months after. Patients with comorbid conditions requiring pain medications were excluded, resulting in a 29,395-patient cohort. Four subgroups were investigated: patients with (1) opioids before hylan G-F 20 (OB; n= 6,609); (2) opioids before and after hylan G-F 20 (OBF; n= 3,320); (3) IACS before hylan G-F 20 (CB; n= 11,162); and (4) IACS before and after hylan G-F 20 (CBF; n= 2,810). All opioids were converted to morphine milligram equivalents (MME).Results OB subgroup patients had a significant decrease (P< 0.01) in total MME (−14.0%), MME per day (−14.2%) and opioid prescription days (−12.6%) after treatment versus before. Only 50.2% of patients prescribed opioids before hylan G-F 20 were prescribed an opioid after treatment. OBF subgroup patients had a significant increase (P< 0.01) in opioid prescription days (7.8%) before versus after treatment. There was a significant decrease (P< 0.01) in the number of IACS after versus before treatment for the Total Cohort (−56.1%), and subgroups CB (−72.6%) and CBF (−4.1%). A total of 74.8% of patients receiving an IACS before treatment did not receive an IACS after treatment.Conclusions Hylan G-F 20 is associated with a reduction in opioid prescriptions and IACS in OAK patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
